{"id":73952,"date":"2026-05-03T19:01:12","date_gmt":"2026-05-03T19:01:12","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/73952\/"},"modified":"2026-05-03T19:01:12","modified_gmt":"2026-05-03T19:01:12","slug":"is-novo-nordisk-a-s-nvo-a-good-stock-to-buy-now","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/73952\/","title":{"rendered":"Is Novo Nordisk A\/S (NVO) A Good Stock To Buy Now?"},"content":{"rendered":"\n

Is NVO a good stock to buy? We came across a\u00a0bullish thesis\u00a0<\/a>on Novo Nordisk A\/S on Unfair Advantage\u2019s Substack by AK. In this article, we will summarize the bulls\u2019 thesis on NVO. Novo Nordisk A\/S’s share was trading at $38.52 as of April 23rd. NVO\u2019s trailing and forward P\/E were 10.65 and 11.38 respectively according to Yahoo Finance.<\/p>\n

\"I'll I’ll Play, Says Jim Cramer About Bristol-Myers (BMY) <\/p>\n

Photo by Myriam Zilles on Unsplash<\/p>\n

Novo Nordisk A\/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. NVO is regaining momentum in the obesity drug market, with its stock rising 18% since prior analysis while still trading at a significant discount to Eli Lilly despite improving fundamentals.<\/p>\n

The company has recently gained a strategic edge through strong early demand for its oral semaglutide and a delay in FDA approval of Eli Lilly\u2019s competing pill, giving Novo a crucial head start in a highly competitive market.<\/p>\n

Read More:\u00a015 AI Stocks That Are Quietly Making Investors Rich<\/a><\/p>\n

Read More:\u00a0Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential<\/a><\/p>\n

Management has acted decisively, appointing a new CEO and board, implementing pricing cuts, and restructuring operations, including a 9,000-employee reduction, signaling a more disciplined and aggressive approach after prior missteps that led to market share losses. While clinical comparisons show Eli Lilly\u2019s tirzepatide has superior weight-loss efficacy at peak doses, real-world data suggests most patients do not reach those levels, narrowing the practical gap between the two drugs.<\/p>\n

Novo\u2019s semaglutide also demonstrates strong cardiovascular benefits, positioning it for expansion into adjacent therapeutic areas. Pricing strategy has emerged as a key differentiator, with Novo offering uniform and significantly lower pricing across doses, improving affordability and competitiveness against both Eli Lilly and compounded alternatives.<\/p>\n

Distribution has also improved materially, highlighted by CVS Caremark favoring Wegovy over Eli Lilly\u2019s Zepbound, which should drive volume growth over time. With a temporary monopoly in GLP-1 pills, favorable pricing, and expanding access channels, Novo Nordisk is well positioned to recapture lost share and capitalize on a large, growing obesity market, supporting a bullish outlook.<\/p>\n

Previously, we covered a bullish thesis<\/a> on Novo Nordisk A\/S (NVO) by Kontra Investments in May 2025, which highlighted the company\u2019s strong financial performance, GLP-1 dominance, and expanding pipeline supporting long-term growth. NVO\u2019s stock price has depreciated by approximately 43.13% since our coverage. AK shares a similar view but emphasizes on Novo\u2019s competitive repositioning through oral semaglutide, pricing, and distribution advantages.<\/p>\n","protected":false},"excerpt":{"rendered":"Is NVO a good stock to buy? We came across a\u00a0bullish thesis\u00a0on Novo Nordisk A\/S on Unfair Advantage\u2019s…\n","protected":false},"author":2,"featured_media":73953,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[276,2141,272,39865,39866],"class_list":{"0":"post-73952","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-eli-lilly","9":"tag-market-share","10":"tag-novo-nordisk","11":"tag-pharmaceutical-products","12":"tag-unfair-advantage"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116512193600576006","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/73952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=73952"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/73952\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/73953"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=73952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=73952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=73952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}